Dual-type dynamic covalent chitosan/whey protein/Sr-doped bioactive glass carriers for hydrophobic compounds: injectable hydrogels and porous scaffolds.

Szymon Salagierski¹, Weronika Gura², Patrycja Domalik-Pyzik³, Elżbieta Menaszek⁴, Timothy E L Douglas⁵, Katarzyna Cholewa-Kowalska², Michał Dziadek⁶

¹Department of Glass Technology and Amorphous Coatings, Faculty of Materials Science and Ceramics, AGH University of Krakow, Krakow, Poland; Department of Materials Engineering, Faculty of Applied Science, University of British Columbia, Vancouver, Canada; School of Engineering, Lancaster University, Lancaster, United Kingdom. Electronic address: salagier@agh.edu.pl.

²Department of Glass Technology and Amorphous Coatings, Faculty of Materials Science and Ceramics, AGH University of Krakow, Krakow, Poland.

³Department of Biomaterials and Composites, Faculty of Materials Science and Ceramics, AGH University of Krakow, Krakow, Poland.

⁴Department of Cytobiology, Jagiellonian University Medical College, Krakow, Poland.

⁵School of Engineering, Lancaster University, Lancaster, United Kingdom.

⁶Department of Glass Technology and Amorphous Coatings, Faculty of Materials Science and Ceramics, AGH University of Krakow, Krakow, Poland. Electronic address: dziadek@agh.edu.pl.

PubMed DOI

Abstract

Chitosan hydrogel-based systems are recognized as versatile platforms for drug delivery and regenerative medicine. However, incorporating hydrophobic bioactive substances remains a significant challenge, typically addressed through complex chemical modifications such as chitosan hydrophobization. This study introduces a straightforward strategy to incorporate lipophilic compounds - retinol and res…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.